Skip to main content

Exclusive: US Retail Marijuana Sales On Pace To Rise 35% In 2019 And Near $30 Billion By 2023

Retail sales of medical and recreational cannabis in the United States are on pace to eclipse $12 billion by the end of 2019 – an increase of roughly 35% over 2018 – and could rise as high as $30 billion by 2023.

That’s according to exclusive projections from the forthcoming 2019 edition of the Marijuana Business Factbook.

Continued sales gains in recreational markets as well as the rapid development of medical marijuana programs in newly legalized states will spur much of that growth over the coming year.

In 2019, new medical markets, including Florida, Maryland, Ohio, Oklahoma and Pennsylvania, saw strong patient demand, broad lists of qualifying conditions and adequate access to dispensaries propel sales beyond initial expectations.

Although medical sales are projected to increase at the same rate as recreational sales in 2019, growth on the medical side of the industry is expected to slow significantly over the long term.

The two largest medical markets in the nation – California and Michigan – will likely see precipitous declines in MMJ sales as rec programs in both states get off the ground. The third-largest medical market – Arizona – is poised to pass adult-use legalization via a ballot initiative in 2020.

Furthermore, only a handful of states remain where medical use is not legal, and many of those – including South Dakota, Wisconsin and Wyoming – have expressed little to no interest in changing that.

As such, the potential for new medical marijuana states coming online and boosting overall sales is beginning to dry up.

On the recreational side, estimated sales in 2018 were revised up slightly from our original forecast at the beginning of 2018.

California’s massive new adult-use industry got off to a slow start, as high taxes, local licensing restrictions and a cumbersome bureaucracy made it difficult for licensed businesses to compete with the state’s entrenched black- and gray-market operators.

But by the end of 2018, the number of licensed retail stores and delivery services in California was up considerably, pushing estimated sales past the $2 billion mark.

Sales in mature markets such as Colorado, Oregon and Washington state continue to grow, although the pace of that growth has slowed. By the end of 2019, each of those states could post single-digit, year-over-year sales gains – the first time that’s happened in a recreational marijuana market.

Nationwide, however, rec sales are set for major growth in the coming years, as California and Massachusetts are expected to hit their strides by 2020 and markets such as Maine and Michigan come online.

Additionally, several state legislatures are actively considering recreational cannabis measures, including Delaware, Illinois, New Hampshire, New York, Rhode Island and Vermont.

By 2023, we project total retail marijuana sales in the United States will reach between $25 billion and $30 billion annually – more than a threefold increase from estimated annual sales in 2018.

Purchase your copy of the Annual Marijuana Business Factbook at mjbizdaily.com/factbook or call us directly at (720) 213-5992, ext 1.

Eli McVey can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/exclusive-us-retail-marijuana-sales-on-pace-to-rise-35-in-2019-and-near-30-billion-by-2023/

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis  sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing  the STATES Act  – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...
Post a Comment
Read more

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...
Post a Comment
Read more